Trial Profile
A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Albiglutide When Used in Combination With Metformin Plus Sitagliptin, Metformin Plus Glimepiride, and Metformin Plus Placebo in Subjects With Type 2 Diabetes
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Oct 2021
Price :
$35
*
At a glance
- Drugs Albiglutide (Primary) ; Glimepiride; Metformin; Sitagliptin
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms HARMONY 3; HARMONY-3
- Sponsors GlaxoSmithKline
- 16 Sep 2016 Results of pooled analysis of four HARMONY programme trials (HARMONY-1, -2, -3 and -5) presented at the 52nd Annual Meeting of the European Association for the Study of Diabetes
- 16 Sep 2016 Results of post-hoc pooled analysis from HARMONY 1-7 trials assessing the relationship between renal function and change in HbA 1c presented at the 52nd Annual Meeting of the European Association for the Study of Diabetes.
- 19 Sep 2014 Results at the end of 3 years presented at the 50th Annual Meeting of the European Association for the Study of Diabetes.